Business Context and Reporting Period
This Form 8-K Current Report was filed by Ball Corporation on November 27, 2015. The filing addresses the ongoing recommended offer by Ball to acquire all issued and to-be-issued shares of Rexam PLC in a cash and stock transaction. The report references a definitive agreement announced on February 19, 2015, and amended on June 12, 2015.
Key Financial Metrics
This filing does not contain specific revenue, profit, cash flow, margin, debt, or liquidity figures for Ball Corporation or Rexam PLC. Instead, it incorporates by reference the following unaudited financial documents:
- Exhibit 99.1: Unaudited pro forma condensed combined financial statements of Ball for the year ended December 31, 2014, and the nine months ended September 30, 2015.
- Exhibit 99.2: Unaudited condensed consolidated financial statements of Rexam and its subsidiaries for the six months ended June 30, 2015, and 2014.
Investors must review the attached exhibits to obtain specific numerical data.
Material Changes
The primary material event is the continued pursuit of the acquisition of Rexam PLC. The filing confirms that the terms of the offer remain subject to the conditions set forth in the original announcement and subsequent amendments. No other material changes to Ball's standalone operations are detailed in the text of this report.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the acquisition and future performance, noting that actual results may differ materially due to various risks. Key risks and uncertainties identified include:
- Acquisition Risks: Failure to satisfy conditions for completion, including receipt of all required regulatory approvals; potential divestitures required for approval; termination of the definitive agreement; and legal proceedings related to the acquisition.
- Packaging Segment Risks: Product demand fluctuations, raw material costs, competitive pricing, climate changes, crop yields, and regulatory changes regarding packaging laws.
- Aerospace Segment Risks: Government and commercial contract funding, authorization, and technical uncertainties.
- General Corporate Risks: Changes in senior management, regulatory actions (including FDA), litigation, labor costs, pension plan performance, and foreign exchange rate fluctuations.
Ball explicitly states it undertakes no obligation to publicly update or revise any forward-looking statements.
Important Facts for Investor Verification
- Verify the specific financial impact of the Rexam acquisition by reviewing the unaudited pro forma statements in Exhibit 99.1.
- Confirm the status of regulatory approvals required to close the Rexam transaction.
- Review the terms of any potential divestitures that may be required to secure regulatory approval for the acquisition.
- Assess the exposure to raw material costs and foreign exchange rates as highlighted in the risk factors.